Abstract:A liposomal formulation was developed for the loading of capecitabine (CAP) and celecoxib (CXB) in the management of cancer and analyzed using a simple, precise, and green method. Modeling of the in vitro drug release and the release kinetics was carried out for the CAP–CXB liposomal formulation. Greenness and whiteness assessments were performed for the developed analytical method. Liposomes have been reported for combination therapy due to their ability to carry both hydrophilic and lipophilic drugs together. The current investigation aims to develop a novel, eco‐friendly, and sustainable reverse‐phase high‐performance liquid chromatography (RP‐HPLC) method for the simultaneous quantification of capecitabine and celecoxib co‐encapsulated in liposomes. The method reported herein uses a C18 column (4.6 × 250 mm2, 5 μm) and a mobile phase consisting of water, and acetonitrile/methanol in a ratio of 60:40, containing 0.1% formic acid in both the phases. The flow rate is maintained at 1 mL/min, with an injection volume of 10 μL in the gradient mode. Detection is set at λmax = 240 nm for capecitabine and 252 nm for celecoxib. The developed liposomes are mono‐disperse with a surface potential of −6.93 mV. The average size of the liposomes is 142 nm. The percentage entrapment efficiency for capecitabine is 52.39 ± 0.94%, and for celecoxib, it is 77.13 ± 0.74%. The Analytical Greenness Metric of 0.61 and Analytical Eco‐Scale Score of 75 signify the greenness of the developed method. Also, the Red‐Green‐Blue model shows excellent whiteness, with a score of 83.2. Thus, the developed method offers a reliable, accurate, precise, buffer‐free, and environment‐friendly RP‐HPLC approach for the simultaneous analysis of capecitabine and celecoxib co‐encapsulated in liposomes.

Integrated Quality by Design (QbD) and Quality Risk Management (QRM) based Liquid Chromatographic Method Development and Validation for Estimation of Capecitabine in Pharmaceutical Dosage Form

Quality by Design Study of the Direct Analysis in Real Time Mass Spectrometry Response

Implementing Analytical Quality by Design (AQbD) Approach for Simultaneous Estimation of Tadalafil and Macitentan by RP-HPLC Method

AQBD Approach in Chemo metric assisted Method Development for the Estimation of Ciprofloxacin and Metronidazole by UV-VIS Spectrophotometry

Analytical QbD-based systematic bioanalytical HPLC method development for estimation of quercetin dihydrate

Analytical Quality by Design Approach for the Development and Validation of Liquid Chromatographic Procedure for the Estimation of Abrocitinib

Quality By Design (QbD): A Comprehensive Understanding and Implementation In Pharmaceuticals Development

Quality by Design approach for a planar chromatographic method for simultaneous estimation of Ivabradine Hydrochloride and Carvedilol in pharmaceutical formulation

A Novel Quality by Design Approach for Developing an HPLC Method to Analyze Herbal Extracts: A Case Study of Sugar Content Analysis.

Stability-indicating HPLC method optimization using quality by design with design of experiments approach for quantitative estimation of organic related impurities of Doripenem in pharmaceutical formulations

Development and validation of RP-HPLC method for estimation of brexpiprazole in its bulk and tablet dosage form using Quality by Design approach

A Quality by Design (QbD) driven gradient high performance liquid chromatography method development for the simultaneous estimation of dasatinib and nilotinib in lipid nanocarriers

A QBD Approach in Chemometric assisted Method Development of Telmisartan and Amlodipine besylate by UV-VIS Spectrophotometry

A Quality by Design (QBD) Approach for the Development and Validation of RP-HPLC Method for the Quantification of Silymarin Tablet

Establishment and Validation of the Quantitative Analysis of Multi-Components by Single Marker for the Quality Control of Qishen Yiqi Dripping Pills by High-Performance Liquid Chromatography with Charged Aerosol Detection.

Quality by design (QbD) in the formulation and optimization of liquid crystalline nanoparticles (LCNPs): A risk based industrial approach

Analytical Quality by Design Oriented Development of the UPLC Method for Analysing Multiple Pharmaceutical Process Intermediates: A Case Study of Compound Danshen Dripping Pills

A sustainable RP‐HPLC method for concurrent estimation of capecitabine and celecoxib in liposomal formulation: Greenness and whiteness appraisal

Quality by Design Approach: Progress in Pharmaceutical method Development and Validation

Implementation of DMAIC principle-based analytical quality by design approach to simultaneous estimation of metronidazole and ofloxacin by HPTLC method

Application of analytical quality by design approach in method development for the simultaneous estimation of levocetrizine hydrochloride and montelukast sodium in their combined dosage form